Biohaven Stock Forum

$Biohaven (BHVN.US)$
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
• Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.
◦ Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.
• Tror...

Here are Wednesday’s biggest calls on Wall Street:
RBC upgrades Estee Lauder $Estee Lauder (EL.US)$ to outperform from sector perform
RBC said it sees an attractive risk/reward.
“We are upgrading EL shares to Outperform. At this point, we believe EPS and investor sentiment have troughed and believe the risk-to-reward profile skews favorable.”
Morgan Stanley reiterates Tesla $Tesla (TSLA.US)$ as overweight
Morgan Sta...

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

$Biohaven (BHVN.US)$ its killing me

it's number 4, $Amylyx Pharmaceuticals (AMLX.US)$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $Biogen (BIIB.US)$ all time low 2 USD
no 2. $Neurocrine Biosciences (NBIX.US)$ all time low 1.9 USD
no 3. $Biohaven (BHVN.US)$ all time low 7 USD
no5. $argenx SE (ARGX.US)$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...

$Biohaven (BHVN.US)$ buying at bid at 43ish over valued

Compared to the success of $Eli Lilly and Co (LLY.US)$ and $NOVO NORDISK A/S (NONOF.US)$, $Pfizer (PFE.US)$ had a rocky start in launching its weight-loss pill. Last December, Pfizer announced that it would discontinue the development of a twice-daily iteration of its weight loss medication danuglipron, due to its unacceptable side effect profile as revealed by a Phase 2b trial. Before that, Pfizer gave up an oral dr...

$Biohaven (BHVN.US)$
looks unstoppable
Kv7
Start q1 ph2/3 in epilepsy
Strat q1 ph2/3 in bipolar disorder
Start q1 ph2 in MDD
Start q2 p2/p3 in ge. epilepsy
They are after $Xenon Pharmaceuticals (XENE.US)$
Ph2 data in OCS Q2
Start h2 ph2 in migrane TRPM3
Start q2 ph2 in MS TYK2
Ph1 data q1 in IgG
ADC Trop2 and more